BOOK NOW AND SAVE UP TO $900!

November 19-21, 2019 | Boston, MA

www.dermatology-drugdevelopment.com

3rd Annual Dermatology Drug Development Summit

Innovating & Accelerating the Development & Commercialization of Dermatology Drugs

Expert Speakers Include:

Sonya Abraham
Head of New Treatment Strategies Immunology
UCB

David Rubenstein
CSO
Dermavant Sciences

Kendall Marcus
Director - Division of Dermatology & Dental Products
FDA

John Armstrong
Head of Global Strategic Opportunities
Galderma

Mandeep Kaur
VP & Head of North America Medical Affairs for Immunology
Sanofi

Michael Howell
Senior Director - Translational Research
Incyte Corporation

Proud to Partner With:

MedPharm · Tergus Pharma (Think Topicals, Think Tergus) · THERAPEUTICS INC. (The Dermatology CRO) · CPL

groupeparima · DOW DEVELOPMENT LABORATORIES, LLC · DPT a Mylan company · proDERM · synteract (BRINGING CLINICAL TRIALS TO LIFE) · bioskin® (unique in dermatology research)

Tel: +1 617 455 4188 **Mail:** info@hansonwade.com

hansonwade

Welcome to the 3rd Dermatology Drug Development Summit

Enhancing development efforts and bringing to market of new and innovative dermatological medicines

The Dermatology Drug Development Summit series is a unique industry-focused forum dedicated to **innovating, accelerating and sharing pharmaceutical best practice on the development and bringing to market of new dermatological medicines** in the treatment of high unmet need.

The dermatology space continues to undergo huge therapeutic innovation and growing competitive pressure, driven by the evolving understanding of the pathophysiology of skin diseases, as well as in the available treatment options for chronic, moderate to severe dermatological conditions and high unmet need.

Join peers and leading industry experts at this comprehensive forum to **debate the end-to-end challenges in dermatology drug development**: from new pathway understandings, to the latest preclinical insights, optimizing formulation strategies, enhancing clinical development plans, or evaluating commercialization approaches. This is a key opportunity to acquire the knowledge and establish connections to **support the efforts at your own organization, advance dermatology pipelines, and benefit patients worldwide**.

Hear what previous attendees have to say

"The Dermatology Drug Development Summit brings highly professionals in the field together and is an excellent opportunity for exchanging ideas and collaboration."

Index Pharmaceuticals

"Thanks for putting together a great conference! It was beneficial to bring together experts from academia, industry and health authorities."

Sienna Biopharmaceuticals

Key Highlights You Cannot Miss

1. **Incyte Corporation** address the use of integrated preclinical models to elucidate on drug efficicacy in dermatology
2. **LEO Pharma** explore the intersection between translational medicine and technology development
3. **Galderma** discuss the potential of personalized medicine to tackle key challenges in patient stratification in immune-mediated inflammatory skin diseases
4. **Sienna Biopharmaceuticals** analyze the advances in clinical endpoints in dermatology
5. **Sanofi** share their experience on integrating Medical Affairs as a key strategic partner in dermatology drug development
6. The **National Eczema Association** give their recommendations on how to effectively integrate the patient's voice and insights into dermatology clinical development
7. The **FDA** delve into regulatory considerations on emerging approaches in dermatology drug development
8. **Krystal Biotech** present their latest clinical trial results on a gene therapy approach for dystrophic EB
9. **Incyte Corporation** share more about their latest clinical data for their JAK1/JAK2 inhibitor for AD and vitiligo
10. **Dermavant Sciences** explore the development story and latest clinical results behind their leading candidate, an AhR agonist for the treatment of psoriasis and AD

EXPERT SPEAKER FACULTY

Adam Raff
Director, Translational Medicine
LEO Pharma

Angela Christiano
Professor & Vice Chair for Research, Department of Dermatology
Columbia University

Brett King
Associate Professor of Dermatology
Yale University School of Medicine

Dan Piacquadio
CEO
Therapeutics Inc.

David Rubenstein
CSO
Dermavant Sciences

Dirk Brockstedt
Senior VP – Biology
RAPT Therapeutics

Elena Rizova
VP & Head of Medical Affairs, Immuno Inflammation
Sanofi

Gurpreet Ahluwalia
Executive Director, Clinical Development
Sienna Biopharmaceticals

John Armstrong
Head of Global Strategic Opportunities
Galderma

John Harris
Vice Chair of Dermatology & Director, Vitiligo Clinic & Research Center
University of Massachusetts Medical School

Jon Lenn
CTO
Medpharm

Kendall Marcus
Director - Division of Dermatology & Dental Products
FDA

Mandeep Kaur
VP & Head of North America Medical Affairs for Immunology
Sanofi

Michael Howell
Senior Director - Translational Research
Incyte Corporation

Michael Kuligowski
Executive Medical Director - Inflammation & Autoimmunity
Incyte Corporation

Ofer Toledano
VP, R&D
Sol-Gel Technologies

Paul Lizzul
CMO
Sienna Biopharmaceuticals

Paul Smith
Senior Director - Pharmacology Non-Oncology
Incyte Corporation

Rajiv Mathur
VP, Product Development
CPL

Sonya Abraham
Head of New Treatment Strategies Immunology
UCB

Suma Krishnan
Founder & COO
Krystal Biotech

Vijendra Nalamothu
Chairman & CEO
Tergus Pharma

Wendy Smith Begolka
Director, Research
National Eczema Association (NEA)

Speaker to Be Confirmed
Groupe Parima

PRE-CONFERENCE LEADERS

Alon Mantel
Skin Biology
Tergus Pharma

Betsy Hughes-Formella
Independent Consultant
Dermatology Drug Development

Frank Sinner
Director, Institute for Biomedicine & Health Sciences
Joanneum Research

Jasmina Jankicevic
Dermatologist
Clinical Development & Medical Affairs Consulting

Robert Rissman
Research Director, Dermatology
Center for Human Drug Research

Sean Andrews
VP, Investor Relations
Sienna Biopharmaceuticals

Tammy Payne
Analytical R&D
Tergus Pharma

JOIN INDUSTRY LEADERS FOR:

7+
Hours of Dedicated Networking

3
Interactive Discussion Sessions

24+
Insightful Case-Studies by Field Experts

3
Focused In-Depth Pre-Conference Workshop Sessions

Tel: +1 617 455 4188 Mail: info@hansonwade.com
www.dermatology-drugdevelopment.com

hansonwade

AGENDA AT-A-GLANCE

Pre-Conference Workshop Day – Nov 19

Workshop A
Novel Translational & Clinical Development Approaches for Topicals

Workshop B
The Future of Drug Development in Dermatology: Indications & Implications

Workshop C
Formulation Development & Drug Delivery of Dermatological Drugs

Start-Up Focus Roundtable
Backing the Bet: Exploring the Challenges of Funding Development

Conference Day 1 – Nov 20

Plenary
Industry Leaders' Perspectives

Speed Networking & Morning Refreshments

Preclinical & Translational	Clinical
Advancing Early Stage Development in Dermatology – Part 1	Next Generation Therapeutic Approaches – Part 1

Lunch & Networking

Innovating Formulation & Delivery Approaches	Next Generation Therapeutic Approaches – Part 2

Afternoon Refreshments & Networking

Plenary
Strategic Insights into Dermatology Drug Development

Conference Day 2 – Nov 21

Plenary
Mapping Out the Dermatology Landscape

Morning Refreshments & Networking

Preclinical & Translational	Clinical
Advancing Early Stage Development in Dermatology – Part 2	Building a Robust Path to Clinic

Lunch & Networking

Plenary
Patient-Facing Dermatology Drug Development

Close of Meeting

CONFERENCE DAY ONE
WEDNESDAY, NOVEMBER 20, 2019

Elena Rizova
VP & Head of Medical Affairs, Immuno Inflammation
Sanofi

8.45 Chair's Opening Remarks

Industry Leaders' Perspectives

Elena Rizova
VP & Head of Medical Affairs, Immuno Inflammation
Sanofi

9.00 Keynote: Advancing Dermatology Medicines

- What have we learnt from the latest therapeutic breakthroughs in dermatological inflammatory diseases?
- What is the next frontier in dermatology drug development?
- Bridging the gap between science and patient

9.30 Industry Leaders Panel: Pioneering in the "Golden Age" in Dermatology

- Exploring the "Golden Age" in dermatology drug development – key advances and challenges
- Discussing what success looks like in derm drug development
- What's next? – exploring new indications, new targets, new personalized medicine approaches
- Addressing unmet need – discussing drug development in rare conditions
- Navigating the fiercely competitive topical space

Elena Rizova
VP & Head of Medical Affairs, Immuno Inflammation
Sanofi

Paul Lizzul
CMO
Sienna Biopharmaceuticals

Sonya Abraham
Head of New Treatment Strategies Immunology
UCB

10.15 Speed Networking

This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the dermatology field and establish meaningful business relationships.

10.45 Morning Refreshments

PRECLINICAL & TRANSLATIONAL	CLINICAL
Advancing Early Stage Development in Dermatology – Part 1	**Next Generation Therapeutic Approaches – Part 1**

11.15 Elucidating Drug Efficacy Via Integrated Preclinical Models - Bridging Molecular, Cellular & Tissue Analysis

- Discussing potential inflammatory in vivo/ex vivo/in vitro skin models
- Modulating of pruritus associated with allergic dermatitis
- Illustrating the value of an integrated preclinical research strategy using a clinical stage case study

Paul Smith, Senior Director - Pharmacology Non-Oncology, **Incyte Corporation**

11.15 JAK Inhibitors in Alopecia Areata & Other Dermatologic Diseases

- Exploring the genetic and immunological basis of alopecia areata
- Discussing the rationale for the use of JAK inhibitors in alopecia areata
- Understanding the broader rationale for the use of JAK inhibitors in other dermatological diseases

Angela Christiano, Professor & Vice Chair for Research, Department of Dermatology, **Columbia University**

11.45 Translational Research in Vitiligo: Launching a New Era of Targeted Treatments

- Exploring vitiligo, an autoimmune disease of the skin with significant unmet medical need
- Understanding how vitiligo is driven by immune signaling through IFNg, and therapies that target this pathway show promise as effective new treatments
- Discussing how relapse occurs in up to 40% of vitiligo patients after stopping therapy and this is due to autoreactive resident memory T cells that can be targeted by blocking IL-15

John Harris, Vice Chair of Dermatology & Director, Vitiligo Clinic & Research Center, **University of Massachusetts Medical School**

11.45 Ruxolitinib Cream in The Treatment of Atopic Dermatitis & Vitiligo

- Describing ruxolitinib cream, a JAK1/JAK2 inhibitor
- Exploring phase 2 study outcomes of ruxolitinib cream in patients with atopic dermatitis and vitiligo
- Analyzing key learnings so far

Michael Kuligowski, Executive Medical Director – Inflammation & Autoimmunity, **Incyte Corporation**

12.15 Lunch & Networking

Innovating Formulation & Delivery Approaches

1.45 Making a Porsche Out of Your Old Chevy: How Sol-Gel Turned an Old Drug into a Novel Rosacea Treatment

- Exploring the secrets behind Sol-Gel's topical drug delivery system
- Delving into the challenges in treating papulopustular rosacea (PPR)
- EPSOLAY – the most effective treatment for PPR

Ofer Toledano, VP, R&D, **Sol-Gel Technologies**

2.15 Session Reserved for Groupe Parima

- More information coming soon

2.30 Innovation in Topical Product Development

- Addressing formulation considerations and novel approaches
- Exploring new options for product packaging formats

Rajiv Mathur, VP, Product Development, **CPL**

Next Generation Therapeutic Approaches – Part 2

1.45 Sarcoidosis & Granuloma Annulare: Emerging Pathways & Treatment

- Detailing on the poor understanding of the pathogenesis of granulomatous disorders, including sarcoidosis and granuloma annulare
- Understanding the significant burden of these diseases – therapies are lacking, and so there is significant unmet need
- Emerging data using JAK inhibitors for the treatment of sarcoidosis and granuloma annulare illuminates pathomechanism and may promise targeted therapy

Brett King, Associate Professor of Dermatology, **Yale University School of Medicine**

2.15 Krystal's Engineered HSV-1 Vectors Efficient Vehicles for Local Delivery of Exogenous Genetic Materials to Skin Cells

- Discussing how vector technology can be used to treat monogenic skin diseases
- Describing how the vector has high payload capacity and is non-integrating with a good safety profile
- Repeating administration with low immunogenicity
- Exploring the scalable manufacturing to process to make this a viable low cost gene therapy drug product

Suma Krishnan, Founder & Chief Operating Officer, **Krystal Biotech**

2.45 Afternoon Refreshments & Networking

Strategic Insights Into Dermatology Drug Development

Jon Lenn
CTO
Medpharm

3.15 Topical Drug Development: Breaking Through Boundaries

- Understanding the challenges and opportunities within the topical and transdermal industry
- De-risking the pharmaceutical pipeline to help ensure your chances of success in the clinic
- Influencing key stakeholders to ensure your success

Mandeep Kaur
VP & Head of North America Medical Affairs for Immunology
Sanofi

3.45 **The Role of Medical Affairs in Dermatology as a Strategic Partner**

- More information coming soon

Vijendra Nalamothu
Chairman & CEO
Tergus Pharma

4.15 **Topical Delivery – The Importance of the Right Formulation in Topical Drug Development**

- Addressing the importance of the right formulation in topical therapies
- Exploring the influence of formulation components and properties in skin absorption and efficacy
- Discussing good formulation development practices: preformulation studies, selection of excipients, early stability studies, cell line/tissue toxicological studies, IVRT and skin penetration studies, and formulation development and optimization

Elena Rizova
VP & Head of Medical Affairs, Immuno Inflammation
Sanofi

4.45 **Chair's Closing Remarks**

5.00 **Poster Session & Drinks Reception**

After the formal presentations have finished, the learning and networking carries on. The Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session scientific posters will be presented on novel targets, drugs with new mechanisms of action, preclinical models, and latest progress in clinical programs.

"The Dermatology Drug Development Summit is an event with high quality attendees providing great opportunity for sharing experiences and networking."

Pierre Fabre

CONFERENCE DAY TWO
THURSDAY, NOVEMBER 21, 2019

Mapping Out The Dermatology Landscape

Mandeep Kaur
VP & Head of North America Medical Affairs for Immunology
Sanofi

8.15 **Chair's Opening Remarks**

Kendall Marcus
Director - Division of Dermatology & Dental Products
FDA

8.30 **Regulatory Perspectives – Emerging Approaches in Dermatology Drug Development**

- Addressing the utilization of digital tools in dermatology clinical trials
- Demonstrating efficacy in Hidradenitis suppurativa – exploring clinical endpoints, new scoring systems and clinical trial design considerations in HS

9.00 **Dedicated Q&A Session**

Sonya Abraham
Head of New Treatment Strategies Immunology
UCB

9.15 **"Golden Age" in Dermatology Drug Development – What Lessons Can Be Learnt from Rheumatic Inflammatory Disease?**

- Exploring key advances and challenges in derm drug development
- Aspiring to personalized medicine

Dan Piacquadio
CEO
Therapeutics Inc.

9.45 **Fail Early, But Try Not to Fail Often**

- Going from product concept to approval - avoiding CMC, nonclinical, clinical, regulatory and other failure potholes
- Understanding how success vs. failure is a team responsibility
- Sharing the risk – partnering of an asset as a failure mitigation strategy

10.15 **Morning Refreshments & Networking**

PRECLINICAL & TRANSLATIONAL

Advancing Early Stage Development in Dermatology – Part 2

11.15 **Precision Dermatology Through the Optics of Omics**

- Using Omics approaches to understand disease heterogeneity and pathogenesis
- Integrating precision medicine approaches in clinical trials
- Defining innovative approaches to predictive medicine

Michael Howell, Senior Director - Translational Research, **Incyte Corporation**

CLINICAL

Chair: Jasmina Jankicevic, Dermatologist, Clinical Development & Medical Affairs Consulting

Building a Robust Path to Clinic

11.15 **The Intersection of Translational Medicine & Technology Development**

- Understanding the need for target identification with a temporal and spatial context within dermatology
- Exploring the unique opportunity for technology development in dermatology
- Discussing how translational medicine can facilitate technology integration into the drug development value chain

Adam Raff, Director, Translational Medicine, **LEO Pharma**

11.45 Tapinarof & the Aryl Hydrocarbon Receptor (Ahr) in Psoriasis & Atopic Dermatitis: Case Study in Novel Target Validation

- Aryl Hydrocarbon Receptor: structure, function and biology
- Therapeutic versus pathologic AhR ligands
- Tapinarof, a novel AhR agonist being developed as a differentiated therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream for the treatment of psoriasis and atopic dermatitis

David Rubenstein, CSO, **Dermavant Sciences**

11.45 The Potential & Challenges of Patient Stratification in Immune-Mediated Inflammatory Skin Disease

- Providing a brief background on atopic dermatitis and psoriasis
- Overviewing recent achievements with novel treatments and the challenges that remain
- Exploring the potential of personalized medicine approaches to the challenges that remain

John Armstrong, Head of Global Strategic Opportunities, **Galderma**

12.15 RPT193 – A potent, selective oral CCR4 Antagonist for the treatment of Atopic Dermatitis

- Exploring the role of Th2 cells in atopic dermatitis and the contribution of CCR4-mediated Th2 migration to the disease
- Introducing the RPT193, a novel oral CCR4 antagonist
- Describing preclinical efficacy of RPT193 in various Th2 driven allergic disease mouse models
- Description of the clinical development plan for RPT193

Dirk Brockstedt, Senior VP of Biology, **RAPT Therapeutics**

12.15 Advancing Clinical Endpoints in Dermatology

- Exploring primary and secondary endpoints used in clinical trials for key dermatological indications
- Discussing the role of endpoints in regulatory approval
- Analyzing the role of endpoints in defining and communicating clinically meaningful benefits to different stakeholders (prescribing physician, patient, payer or marketing)

Gurpreet Ahluwalia, Executive Director, Clinical Development, **Sienna Biopharmaceuticals**

12.45 Lunch & Networking

Patient-Facing Dermatology Drug Development

Wendy Smith Begolka
Director, Research
National Eczema Association (NEA)

1.45 Patient Engagement: Turning Buzzwords into Action

- Establishing patients as partners in drug development
- Exploring opportunities for meaningful engagement and follow-through
- Translating patient insights from clinical trials to clinical practice

2.15 Panel Discussion: Promoting Patient-Centricity in Dermatology

- Establishing patient-facing protocol development and design of development programs
- Discussing the evolution of Patient Reported Outcomes in dermatology
- Promoting digital patient tools in dermatology clinical trials (engagement, recruitment, data collection)

Wendy Smith Begolka
Director, Research
National Eczema Association (NEA)

Jasmina Jankicevic
Dermatologist
Clinical Development & Medical Affairs Consulting

John Armstrong
Head of Global Strategic Opportunities
Galderma

Mandeep Kaur
VP & Head of North America Medical Affairs for Immunology
Sanofi

2.45 Chair's Closing Remarks

3.00 End of Dermatology Drug Development Summit 2019

PRE-CONFERENCE WORKSHOP DAY
TUESDAY, NOVEMBER 19, 2019

Workshop A

8:00am – 10:45am

Novel Translational & Clinical Development Approaches For Topicals

An optimized early drug development program should meet the double challenge to correctly identify and predict target engagement in the patient and de-risk later stage clinical development for both efficacy and safety. By using a creative approach for topical product development which integrates innovative methods and translational models into early phase preclinical and clinical research, it is possible to **increase efficiency and speed-up development time of dermatological products.**

In this workshop, real-life data and hypothetical examples will be used to **explore alternative strategies for early development of topical products**. Cases will be shown illustrating how the measurement of real-time PK/PD, establishing proof-of-pharmacology in challenge models, or assessing safety via dermal PK can be applied to de-risk development and build confidence.

Development roadmaps will be presented to address the key challenges and pitfalls in new drug development scenarios, including:

- Drawing on systems dermatology: novel insight from pathophysiology and implications for drug developers
- Translating ex vivo and animal models to early human POC study designs
- NCE development: approaches for bridging of concept and final formulations
- Innovation in 505(b)2 or hybrid developments by bridging for safety and efficacy
- Add dermal PK/PD to your classic phase 1 study
- Efficient topical development of re-purposed APIs
- Place for novel methods and novel endpoints
- Understanding drug action and rapid dose selection in models
- The value of biomarkers
- Regulatory implications FDA vs. EMA

Workshop Leaders

Betsy Hughes-Formella
Independent Consultant,
Dermatology Drug Development

Frank Sinner
Director, Institute for
Biomedicine & Health Sciences
Joanneum Research

Robert Rissman
Research Director, Dermatology
Center for Human Drug Research

> "A very good meeting in terms of presentation topics, interactive workshops and networking."
>
> **Celgene Corporation**

PRE-CONFERENCE WORKSHOP DAY
TUESDAY, NOVEMBER 19, 2019

Workshop B

11:00am – 1:45pm

The Future of Drug Development in Dermatology: Indications & Implications

The spurt of innovation in dermatology drug development continues. Current and emerging drugs in development for skin diseases are moving boundaries of possible in efficacy, safety, and convenience for patients.

However, is there a correlation between development intensity and indication diversity? Are pharma/biotech companies in dermatology gravitating primarily towards several indications? What regulatory and commercial implications will that generate? What dermatological indications are crying for attention and how to prioritize areas of unmet needs based on the asset at hand?

This workshop is your opportunity to gain:

- Insights into pipeline optimization strategies and timely drug development
- New perspectives on recent occurrences in dermatology space
- Actionable learnings from instructive case studies

Key topics to be addressed include:

- Current and future dermatology drug landscape
- Differentiation strategies in the busy development space
- Unmet-need-driven innovation
- Building patients' perspectives into the foundation of product strategy
- Acceleration of the drug development process

In this engaging workshop, Dr. Jasmina Jankicevic will deliver a discussion packed with relevant content and crisp-clear takeaways. This interactive session will enable you to strategically stimulate innovation in your organization, to optimize your pipeline, and to maximize the value of your development programs.

Workshop Leader

Jasmina Jankicevic
Dermatologist
Clinical Development & Medical Affairs Consulting

"I was able to get something out of each presentation. It was a total success in my opinion."

GlaxoSmithKline

PRE-CONFERENCE WORKSHOP DAY
TUESDAY, NOVEMBER 19, 2019

Workshop C

2:00pm – 5:00pm

Formulation Development & Drug Delivery of Dermatological Drugs

A key area of focus for drug developers working in dermatology is to ensure the optimization of drug delivery platforms and formulation approaches. In this workshop, you will have the opportunity to gain in-depth insights from leading experts in this space that will help you advance your topical development.

Key areas to be discussed include:

- **Early Development, Skin Biology and Skin Permeation**
  - *Leveraging Skin Biology in Dermal Drug Development:* The use and the application of different variations of human skin equivalents or human ex vivo skin culture models (which have become of particular interest in the pharmaceutical industry to de-risk topical drug development of new drugs and optimize formulation development) will be discussed as well as its limitations.
  - *Utilizing in Vitro Permeation Testing (IVPT) as a tool for developing topical drug products:* Discussing IVPT as a tool in the screening study of new molecules, evaluation of formulations prior to a regulatory filing, post-approval claims support studies, and as a BE/BE approval tool for generics, etc.
- **Product Development:** focusing on formulation development of topical drug products: early clinical candidates, late-stage formulations and generics with an emphasis on QbD.
- **Formulation Development:** formulation paradigm for topical drug development, skin delivery-pragmatic approaches for skin permeation enhancement, the impact of formulations on performance and safety, linking innovation with clinical de-risking, generics (BA/BE waiver approaches).
- **Manufacturing Process Development:** scale-up and commercialization, quality by Design (QbD), novel packaging approaches, phase appropriate Clinical Trial Material (CTM), Scale Up and Post Approval Changes (SUPAC)
- **Analytical Research & Development**

This interactive and comprehensive session will allow you to **streamline and boost innovative delivery and formulation approaches** that match the potential of your drug candidates.

Workshop Leaders

Vijendra Nalamothu
Chairman & CEO
Tergus Pharma

Tammy Payne
Analytical R&D
Tergus Pharma

Alon Mantel
Skin Biology
Tergus Pharma

> "The talks were high quality and the interaction among participants was excellent."
>
> **Genentech**

PRE-CONFERENCE WORKSHOP DAY TUESDAY, NOVEMBER 19, 2019

Start-Up Focus Roundtable

5:15pm – 7:00pm

Backing the Bet: Exploring the Challenges of Funding Development

How does a company maximize its ability to secure adequate funding for continued development of its asset(s)?

At a critical booming point in the dermatology drug development space, **early stage start-ups exploring the opportunity to bring innovative programs to life face fierce competitive and financial pressures**. This session will be an opportunity to discuss with peers and hear the perspectives of seasoned experts in investment and funding for life sciences companies on **how to tackle key challenges to securing funding and investment for early stage development pipelines.**

The session will explore key topics, including:

- Going public vs staying private
- Judging the macro environment
- The stories investors buy

Workshop Leaders

Sean Andrews
VP, Investor Relations
Sienna Biopharmaceuticals

More guest speakers to be announced soon.

Free Registration for this Session Will Open On October 14, 2019

PARTNERS

Expertise Partner

MedPharm is the world leading specialist pharmaceutical development company, committed to the creation and development of bespoke topical and transdermal formulations for application to the skin, nail, mucous membranes, eye, nose and lung. Alongside developing its own patented dermal drug delivery technologies, MedPharm uses its experience to support customers through regulatory approval previously resulting in biowaivers for generic submissions from regulatory authorities and marketing authorisations for over 60 products in the US and Europe.

www.medpharm.com

Expertise Partner

Tergus is a full-service topical pharmaceutical research, development, testing and manufacturing company. The company is an industry leaderfor more than 20 years with a state-of-the-art facility in Durham, North Carolina. The company has a long and stellar reputation for delivering quality and results for clients from formulation through manufacturing, which is why people say, “Think Topical. Think Tergus”

www.terguspharma.com

Expertise Partner

San Diego based, Therapeutics, Inc., The Dermatology CRO was founded in 1997. Approximately 90% of our activities are focused on developing dermatology products. TI is the only dermatology-focused CRO that provides all services required to move a product concept through non-clinical and clinical stages to FDA approval. During the last 5 years: TI managed >12,000 subjects in >80 clinical studies and filed 18 INDs and IDEs in a variety of drug, device and biologic programs.

www.therapeuticsinc.com

Innovation Partner

CPL is a leading contract development and manufacturing organization providing product development and commercial manufacturing of non-sterile liquid and semisolid pharmaceutical and regulated OTC products. Our facilities are registered by FDA and Health Canada and maintain an outstanding record of regulatory compliance. CPL is a reputable contract manufacturer known to provide high quality product with exceptional service. By offering a full-spectrum partnership – from development to commercial production – CPL creates strategic, long-term relationships with our customers.

www.cplltd.com

Innovation Partner

Groupe PARIMA is a CDMO specialized in liquid, suspension, semi-solid and metered-dose-spray dosage forms. We have the expertise to support the full lifecycle of your product from initial development and clinical lots to commercial manufacturing. With presence in over 30 countries, we can serve as your gateway to overseas markets. In our US-FDA and Health Canada inspected facility, we currently manufacture drug products for the US, Canadian, European, Asian and Latin American markets

www.groupeparima.com

Exhibitor

Dow Development Lab’s core expertise is in the design, development and manufacture of topical drug products for dermatology. The formulation, analytical, production, quality, and clinical labeling groups have decades of experience moving products quickly toward regulatory approval. Always with the patient in mind, products are designed to be disease-compatible and cosmetically elegant. Dow Development Labs works seamlessly with its parent company Symbio, a specialty clinical CRO, to rapidly advance client dermatological programs through all stages of clinical development.

www.dowdevelopmentlabs.com

Exhibitor

DPT, a Mylan company, is a leading contract development and manufacturing organization, recognized for its excellence in semi-solid and liquid dosage forms. Backed by a team of approximately 1,000 employees in San Antonio, Texas, DPT has unmatched experience, resources and capacity to efficiently serve your pharmaceutical development and manufacturing needs – no matter the scope. From concept to commercialization, DPT remains committed to exceeding expectations for quality and service.

www.dptlabs.com

proDERM

Exhibitor

proDERM is an internationally renowned CRO with a specialized focus on studies relating to skin and mucous membranes, offering customized and innovative solutions to Sponsors worldwide, running studies in our dedicated clinic and in our growing network of qualified sites in Germany. proDERM has established an excellent reputation as a high-quality provider of trial services, on the basis of an outstanding technical set-up and expertise, including Confocal Microscopy, Raman Spectroscopy and many state-of-the art skin measuring devices.

www.proDERM.de

synteract
BRINGING CLINICAL TRIALS TO LIFE

Exhibitor

Synteract is an innovative CRO providing full-service, Phase I-IV services to biopharma companies in bringing new medicines to market. We align our operational excellence, therapeutic expertise and the right technology to support each client's clinical development needs. Over its nearly 30-year history, Synteract's leadership has been proven in the core development areas of dermatology, oncology, neuro-degenerative disorders, rare/orphan disease, and pediatrics, and has contributed to more than 240 product approvals in these and additional therapeutic areas.

www.synteract.com

bioskin®
unique in dermatology research

Event Partner

Bioskin is a leading CRO with unique understanding and capabilities for both early and late phase dermatological clinical trials. Recognized by global companies as a valuable partner in studies for drugs, medical devices, food supplements and advanced cosmetics since 1992, bioskin offers early phase safety and Proof-of-Concept studies, vasoconstrictor assays according to FDA guideline, global Phase II – IV trials for NCEs, new formulations with known actives as well as consulting in the field of dermatology.

www.bioskinCRO.com

Who You'll Meet

ATTENDANCE BY SECTOR*



ATTENDANCE BY SENIORITY*



- C-level: 19%
- VP & Head: 26%
- (Senior) Director: 32%
- Other: 23%

* Based on 2018's DDD Summit Boston attendance

FOR MORE INFORMATION ABOUT PARTNERSHIP OPPORTUNITIES, PLEASE CONTACT:

Jacob Roberts-Kendall
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.dermatology-drugdevelopment.com/register

Tel: +1 617 455 4188

Email: register@hansonwade.com

TEAM DISCOUNTS*

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5+ delegates**

*Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

SECURE YOUR PLACE

Industry	Register & Pay before Friday August 30, 2019	Standard Pricing
PLATINUM: Conference + 3 Workshops	$4096 **(save $900)**	$4696 **(save $300)**
GOLD: Conference + 2 Workshops	$3497 **(save $800)**	$4097 **(save $200)**
SILVER: Conference + 1 Workshop	$2898 **(save $700)**	$3498 **(save $100)**
BRONZE: Conference Only	$2299 **(save $600)**	$2899
Workshops (Each)	$699	

Academic, Non-Profit & Start-Up*	Register & Pay before Friday August 30, 2019	Standard Pricing
PLATINUM: Conference + 3 Workshops	$2496 **(save $600)**	$2796 **(save $300)**
GOLD: Conference + 2 Workshops	$2197 **(save $500)**	$2497 **(save $200)**
SILVER: Conference + 1 Workshop	$1898 **(save $400)**	$2198 **(save $100)**
BRONZE: Conference Only	$1599 **(save $300)**	$1899
Workshops (Each)	$399	

*T&Cs Apply: Start-up rate is subject to organizer approval. Please visit the event website for more details.





VENUE

Aloft Boston Seaport District
401-403 D Street
Boston, MA 02210, USA

For further information or assistance, please visit www.marriott.co.uk/hotels/travel/bosal-aloft-boston-seaport-district/

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH